BEIJING, June 18 (Xinhua) -- Sino Biopharmaceutical Limited, or Sino Biopharm, has been selected on the list of the top 50 global pharmaceutical companies (Pharm Exec 50), making it on this list for the sixth consecutive year.
The American magazine Pharmaceutical Executive (PharmExec) has recently unveiled its newest ranking of the top 50 global pharmaceutical companies where the Sino Biopharm advanced to 38th place globally, up one position from last year.
Being recognized on the global stage for six years straight reflects the international community's appreciation of the company's innovative efforts, said Xie Qirun, chairman of the Sino Biopharm.
As a leading innovative research and development-driven pharmaceutical conglomerate in China, Sino Biopharm has been constantly focused on innovation.
In 2023, the company invested 4.4 billion yuan in R&D, representing 16.8 percent of its revenue. Notably, 77 percent of this investment was dedicated to innovative drug development.
"In 2024, we anticipate several new products to be approved and launched, marking a significant period for our innovation pipeline. By 2025, we expect to have around 20 innovative products, with nearly half of our revenue coming from these innovations," Xie added.
PharmExec is a leading publication in the global pharmaceutical industry. Pharm Exec 50, now in its 24th year, ranks companies primarily based on prescription drug sales, with data provided in partnership with Evaluate Ltd. (Edited by Zhao Wanru, Hu Pingchao, hupingchao@xinhua.org)
A single purchase
